Affordable Access

deepdyve-link
Publisher Website

Comparison of the effects of aflibercept and dexamethasone in central retinal vein occlusion with serous retinal detachment.

Authors
  • Bayat, Alper Halil1
  • Akpolat, Çetin2
  • Livan, Hazal3
  • Bölükbaşı, Selim3
  • Elçioğlu, Mustafa Nuri3
  • 1 Department of Ophthalmology, Medipol University, İstanbul, Turkey. , (Turkey)
  • 2 Department of Ophthalmology, Şişli Etfal Research and Traning Hospital, University of Health Sciences, İstanbul, Turkey. , (Turkey)
  • 3 Department of Ophthalmology, Okmeydanı Research and Traning Hospital, University of Health Sciences, İstanbul, Turkey. , (Turkey)
Type
Published Article
Journal
Clinical & experimental optometry
Publication Date
May 01, 2022
Volume
105
Issue
4
Pages
404–409
Identifiers
DOI: 10.1080/08164622.2021.1927676
PMID: 34139964
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Previous studies have shown the efficacy of aflibercept and dexamethasone in central retinal vein occlusion. However, the efficacy of these two drugs in central retinal vein occlusion accompanied by serous macular detachment has not been investigated and compared. This results in a search for more precise data to evaluate the effects of two drugs in real-world studies. The aim of this study is to compare the efficacy of intravitreal aflibercept and dexamethasone implantation injections in central retinal vein occlusion accompanied by serous retinal detachment. Sixty-eight eyes of 68 patients with treatment-naive macular oedema post-central retinal vein occlusion were enrolled in the retrospectively designed study. All of the patients had serous retinal detachment at baseline. The patients received three intravitreal aflibercept injections with an interval of four weeks and followed by pro re nata treatment protocol (intravitreal aflibercept group, n = 37) or a single dose dexamethasone implantation injection (dexamethasone implantation group, n = 31). Best-corrected visual acuity, central retinal thickness and the height of serous retinal detachment parameters were compared at baseline, and in the first, second, third and sixth months. The groups were similar in terms of baseline characteristics (p > 0.05 for all). The visual gain was greater in the intravitreal aflibercept group (p = 0.013). While the intravitreal aflibercept group had a significant central retinal thickness decrease in the first and sixth months (p = 0.011 and p = 0.001, respectively), this superiority was not observed during the entire follow-up period (p = 0.212). There was no difference in serous retinal detachment resolution between the groups (p = 0.403). Two patients in the intravitreal aflibercept group (5.4%) and five patients in the dexamethasone implantation group (16.1%) had serous retinal detachment at the final visit (p = 0.158). Both intravitreal aflibercept and dexamethasone implantation injections seemed to be effective in the treatment of central retinal vein occlusion with serous retinal detachment. Intravitreal aflibercept treatment yielded better results in terms of visual gain and showed a faster anatomical response.

Report this publication

Statistics

Seen <100 times